1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC.

Slides:



Advertisements
Similar presentations
Comparing different treatments How can we decide?.
Advertisements

Measuring outcomes Emma Frew October Measuring outcomes Learning objectives By the end of the session students should be able to – Explain how different.
Quality of life in relation to costs
1 Could there be a single European EQ tariff? Jan J.V. Busschbach, Ph.D. Former address: –iMTA, Erasmus university Present address: –Medical Psychology.
COCOM Kwaliteit van leven in maat en getal Jan van Busschbach.
1 The Future of Quality of Life Assessment in Cost-Effectiveness Research Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
1 The QALYs debate  Prof. dr. Jan J.V. Busschbach, Ph.D.  Erasmus MC  Institute for Medical Psychology and Psychotherapy.
1 Does it make a difference for the patient? Survival & Quality of life  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and.
1 A Health Economic View on Borderline Personality Disorder Prof. dr. Jan Busschbach Viersprong Institute for studies on Personality Disorders Medical.
Big Q and Little Q revisited Christopher McCabe PhD Capital Health Endowed Research Chair in Emergency Medicine Research.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Prof. dr. Jan van Busschbach Department of Medical Psychology & Psychotherapy Erasmus MC.
1 Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
Health Economics II –2010 Health Economic Evaluations Part III Lecture 2 Cost-effectiveness analysis QALYs and cost-utility analysis Nils-Olov Stålhammar.
QALYs and Ethics Prof. dr. Jan van Busschbach 11.
Quality of life Assessment introduction
1 EuroQol EQ-5D Jan J. V. Busschbach, Ph.D Psychotherapeutic Centrum ‘De Viersprong’, Halsteren Department of Medical.
Measuring and valuing health outcome Montarat Thavorncharoensap, Ph.D. 1: Faculty of Pharmacy, Mahidol University 2. HITAP, Thailand.
QALYs and Ethics Is there an ethical / valid alternative?
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
1 Health Economics  Comparing different allocations  Should we spent our money on Wheel chairs Screening for cancer  Comparing costs  Comparing outcome.
Measuring the “Q” in QALYs for cost- effectiveness analysis: the EuroQol Group’s approach Valuing health outcomes for healthcare decision making using.
1 Cost-effectiveness in Personality Disorder Dr. J.J.V. Busschbach Psychotherapeutic centre ‘De Viersprong’ –PO Box AA Halsteren
Overview of the EQ-5D Purpose and origins of the descriptive system.
1 The valuation of disease-specific questionnaires for QALY analysis  To rescue data in absence of an utility measure  Growth hormone deficiency in adults.
Is healthcare any good for patients? Measuring health outcomes using EQ-5D Professor Paul Kind Principal Investigator Outcomes Research Group Centre for.
Rescuing Clinical Trial Data For Economic Evaluation
Why use the EQ-5D? What are the alternatives?. What are the alternatives for Direct valuation? Other VAS Time Trade-Off Standard Gamble Willingness to.
EQ-5D AND QUALITY OF LIFE OF OSTEOPOROSIS AT-RISK PATIENTS IN A SWEDISH OSTEOPOROSIS PATIENT REGISTRY Arun Krishna 1, Dan Mellström 2, Zhiyi Li 3, Chun-Po.
1 Reconciliation of Economic Arguments and Clinical Practice Monday November 4, 2002 ISPOR, Rotterdam Jan Busschbach PhD, –Department of Medical Psychology.
1 Patient values or values from the general public.
1 The valuation of disease-specific health states to facilitate economic evaluation E. Kok, E. Stolk, Jan J. v. Busschbach Address: –Jan v. Busschbach.
Quality Adjusted Life Years (QALY)
Interactive Introduction cost effectiveness Jan J. v. Busschbach, Ph.D Viersprong Institute for studies on Personality Disorders (VISPD)
1 Cost effectiveness as argument for reimbursement in prevention Jan J. v. Busschbach, Ph.D. Erasmus MC –Institute for Medical Psychology and Psychotherapy.
1 Interactive introduction in Quality of life Assessment Jan J. v. Busschbach, Ph.D. Department of Medical Psychology and Psychotherapy, Erasmus MC
1 EQ-5D, HUI and SF-36 Of the shelf instruments…..
Patsi Sinnott, PT, PhD, MPH HERC Economics Course April 7, 2010 Introduction to Effectiveness, Patient Preferences and Utilities.
Economic evaluation of psychotherapy for personality disorders: burden of disease and cost-effectiveness Djøra Soeteman Viersprong Institute for Studies.
Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy Viersprong.
11 Cost Effectiveness in Preventing Crime  Jan van Busschbach, Djøra Soeteman  Viersprong Institute for studies on Personality Disorders VISPD  Erasmus.
1 The Cost Effectiveness of Treatment of Personality Disorder  Dr. Jan J.V. Busschbach  PTC De Viersprong, Erasmus MC, Rotterdam, 
Cost-Effectiveness of Psychotherapy for Personality Disorders Soeteman, Busschbach, Verheul.
Cost-effectiveness in the quest to convince the outside world Dr. Jan Busschbach De Viersprong Erasmus MC
1 Health outcome valuation study in Thailand Sirinart Tongsiri Research degree student Health Services Research Unit, Public Health & Policy Department.
1 Cost Effectiveness  Jan J.V. Busschbach, Ph.D.  Viersprong Institute for studies on Personality Disorders VISPD  Erasmus.
1 Interactive Introduction Cost Effectiveness and Psychotherapy Jan J. v. Busschbach, Ph.D. Psychotherapeutic Centrum ‘De Viersprong’, Halsteren
1 The Economics of Health Care and New Technologies Friday October 18, 2002 Between Technology and Humanity, Brussels Jan Busschbach PhD, –Department of.
Hermann P. G. Schneider, Alastair H. MacLennan and David Feeny
1 Value of Information in relation to risk management  Prof. Dr. Jan J.V. Busschbach.
“Introduction to Patient Preference Methods used for QALYs” Presented by: Jan Busschbach, PhD, Chair Section Medical Psychology and Psychotherapy, Department.
Thirty down, only ten to go?! Awareness and influence of a 10-year time frame in TTO Floor van Nooten, Xander Koolman, Werner Brouwer 1 A paper introduced.
Cost-Effectiveness of Psychotherapy (for Personality Disorders) Prof. dr. Jan van Busschbach.
Values Lower Than Death Jan J. v. Busschbach, Ph.D. –Erasmus University Rotterdam institute for Medical Technology Assessment (iMTA) PO box DR.
How to weight cost effectiveness in appraisal NVTAG / CVZ course: The appraisal process, work in progress 22th of April 2009 Jan van Busschbach.
(Cost-)Effectiveness of Psychotherapy for Personality Disorders Jan van Busschbach Prof. Dr. J. van Busschbach Department of Medical Psychology and Psychotherapy.
1 Quality of life and Cost-Effectiveness An Interactive Introduction Prof. Jan J. v. Busschbach, Ph.D. Erasmus MC Medical Psychology and Psychotherapy.
Who is involved in making NICE guidance recommendations and what evidence do they look at? Heidi Livingstone, Senior Public Involvement Adviser.
1 Are values cultural determined…..  Many believe that QoL is cultural determined  One of the starting points of the EuroQol group.
1 Cost-Effectiveness in Medicine An Interactive Introduction  Jan J. v. Busschbach, Ph.D.  Erasmus MC Institute for Medical Psychology and Psychotherapy.
1 VAS, SG, TTO and PTO An Interactive Introduction.
1 Utilization of Quality of Life Research in Decision-Making and Policy  Prof. Dr. Jan J.V. Busschbach  Erasmus MC, Rotterdam, The Netherlands  Section.
The burden of disease in patients with personality disorder indicated for psychotherapy: Arguments for necessity of care Djøra Soeteman, MSc
Prof. Dr. Jan J.V. Busschbach
The valuation of disease-specific questionnaires for QALY analysis
Is healthcare any good for patients
Measuring outcomes Emma Frew October 2012.
How to Measure Quality of Life
Presentation transcript:

1 Dyslexia and Cost Effectiveness Prof. dr. Jan van Busschbach De Viersprong Erasmus MC

2 Health Economics  Comparing different allocations  Should we spent our money on Wheel chairs Screening for cancer Dyslexia treatment  Comparing costs  Comparing outcome  Outcomes must be comparable  Make a generic outcome measure

3 Outcomes in health economics  Specific outcome are incompatible  Allow only for comparisons within the specific field Clinical successes: successful operation, total cure Clinical failures: “events” Number of correct spelled words  Generic outcome are compatible  Allow for comparisons between fields Life years Quality of life  Most generic outcome  Quality adjusted life year (QALY)

4 Quality Adjusted Life Years (QALY)  Multiply life years with quality index  Quality of life index  1.0 = normal health  0.0 = death (extremely bad health)  Example  Losing sense of sight  Quality of life index is 0.5  Life = 80 years  0.5 x 80 = 40 QALYs

5 QALY  Quality Adjusted Life Years  Area under the curve

6  A new wheelchair for elderly (iBOT)  Special post natal care Which health care program is the most cost-effective?

7  A new wheelchair for elderly (iBOT)  Increases quality of life = 0.1  10 years benefit  Extra costs: $ 3,000 per life year  QALY = Y x V(Q) = 10 x 0.1 = 1 QALY  Costs are 10 x $3,000 = $30,000  Cost/QALY = 30,000/QALY  Special post natal care  Quality of life = 0.8  35 year  Costs are $250,000  QALY = 35 x 0.8 = 28 QALY  Cost/QALY = 8,929/QALY Which health care program is the most cost-effective?

Citations in PubMed

9 QALY league table

10 Dyslexia and QALYs  Request from CvZ  Cost effectiveness protocol dyslexia treatment  According to best standards Pharmacoeconomics guidelines  5 weeks….  Leona Hakkaart  Costs  Elly Stolk  Outcome (Quality of Life)

11 Model based on Patty Gerretsen 70 % 30 %

12 Parameters  70% effectiveness  N = 233, 1 year and 10 year  Gerretsen et al., 2006  Costs  Protocol: €  CAU: € N = 121 pre-treatment Intake Regionaal Instituut voor Dyslexie  children  6% gets diagnostics  1,8% treatment

13 Effect on costs in 4 years 70 % 30 % € € But what about the effects on outcome?

14 Outcome  Disease specific  Better reading skills  Better writing skills  Higher education  But what about generic effects?  Quality of life  QALYs

15 Value health states dyslexia  No dyslexia, Mild, Severe

16 Uni-dimensional value  Like the IQ-test measures intelligence  Ratio or interval scale  Difference 0.00 and 0.80 must be 8 time higher than 0.10  Three popular methods have these pretensions  Visual analog scale  Time trade-off  Standard gamble

17 Visual Analogue Scale  VAS  Also called “category scaling”  From psychological research  “How is your quality of life?”  “X” marks the spot  Rescale to [0..1] Dead Normal health X

18 Time Trade-Off  TTO  Wheelchair  With a life expectancy: 50 years  How many years would you trade-off for a cure?  Max. trade-off is 10 years  QALY(wheel) = QALY(healthy)  Y * V(wheel) = Y * V(healthy)  50 V(wheel) = 40 * 1  V(wheel) =.8

19 Of the shelf instrument: EQ-5D  Patient sample  “Woortblind”  N = 265  Out of 820  Response rate 32.3%  EQ-5D  Patients 0.87 (sd 0.16)  Norm 0.88 (sd 0.16)  MOBILITY  I have no problems in walking about  I have some…….  I am confined to bed  SELF-CARE  I have no problems with self-care  I have some problems…..  I am unable…  USUAL ACTIVITIES  I have no problems with performing my usual activities  I have some problems…  I am unable….  PAIN/DISCOMFORT  I have no pain or discomfort  I have moderate …..  I have extreme……..  ANXIETY/DEPRESSION  I am not anxious or depressed  I am moderately……..  I am extremely….. Not sensitive in Dyslexia

20 Paired comparisons Severe dyslexiaADHASevere dyslexiaCrohnSevere dyslexiaMild Asthma

21 Quality of life weights

22 Costs per QALY  Elementary school €  Basis school  Grammar school €  Middelbare school  Secondary education €  Vervolgonderwijs

23 QALY league table

24 Limitations  Conservative estimates  No involved cost of repeaters  Only costs of CUA in first year  No good estimates of additional income  Limited effect estimates  No RCT  No formal estimates of uncertainty

25 ISPOR 2007

26 Conclusion  Cost per QALY is feasible in dyslexia  Cost per QALY of treatment is reasonable  Cost effectiveness successfully uses as argument in reimbursement  There is a need for better…  Estimates of effects  Estimates quality of life  Models